Tatjana Adzic-Vukicevic1,2, Aleksandra Barac3,4, Ana Blanka-Protic5, Marija Laban-Lazovic5, Bojana Lukovic6, Vesna Skodric-Trifunovic3,5, Salvatore Rubino7. 1. Faculty of Medicine, University of Belgrade, Belgrade, Serbia. abarac@jidc.org. 2. Clinic for Pulmonology, Clinical Centre of Serbia, Dr Koste Todorovića 26, Belgrade, 11000, Serbia. abarac@jidc.org. 3. Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 4. Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia. 5. Clinic for Pulmonology, Clinical Centre of Serbia, Dr Koste Todorovića 26, Belgrade, 11000, Serbia. 6. Department for Microbiology, Clinical Centre of Serbia, Belgrade, Serbia. 7. Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
Abstract
INTRODUCTION: Non-tuberculous mycobacteria (NTM) are ubiquitous organisms associated with various infections. The aim of the study was to determine the most relevant clinical characteristics of NTM during the 7-year period. METHODOLOGY: A retrospective study of NTM infections was conducted between January 2009 and December 2016. The American Thoracic Society/Infectious Disease Society of America criteria were used to define cases of pulmonary or an extrapulmonary site. RESULTS: A total of 85 patients were included in the study. Pulmonary cases predominated 83/85 (98%), while extrapulmonary NTM were present in 2/95 (2%) patients. Overall, ten different NTM species were isolated. The most common organisms were slow-growing mycobacteria (SGM) presented in 70/85 (82.35%) patients. Isolated SGM strains were Mycobacterium avium complex (MAC) in 25/85 (29.41%) patients, M. xenopi in 20/85 (23.53%) patients, M. kansasii in 15/85 (17.65%) patients and M. peregrinum and M. gordonae in 5/85 (5.88%) patients each. Isolated rapid-growing mycobacteria (RGM) strains were M. abscessus in 8/85 (9.41%) patients, M. fortuitum in 4/85 (4.71%) patients and M. chelonae in 3/85 (3.53%) patients. Almost all patients (98%; 83/85) had comorbidities. Among 75 (88.24%) patients who completed follow-up, 59 (69.41%), 10 (11.76%) and 6 (7%), were cured, experienced relapse and died, respectively. CONCLUSION: In the present study, pulmonary NTM infections were more frequent compared to extrapulmonary disease forms. SGM were most common isolates with MAC pulmonary disease the most frequently found. Comorbidities have an important role in NTM occurrence. Further investigation should focus on an NTM drug susceptibility testing.
INTRODUCTION:Non-tuberculous mycobacteria (NTM) are ubiquitous organisms associated with various infections. The aim of the study was to determine the most relevant clinical characteristics of NTM during the 7-year period. METHODOLOGY: A retrospective study of NTM infections was conducted between January 2009 and December 2016. The American Thoracic Society/Infectious Disease Society of America criteria were used to define cases of pulmonary or an extrapulmonary site. RESULTS: A total of 85 patients were included in the study. Pulmonary cases predominated 83/85 (98%), while extrapulmonary NTM were present in 2/95 (2%) patients. Overall, ten different NTM species were isolated. The most common organisms were slow-growing mycobacteria (SGM) presented in 70/85 (82.35%) patients. Isolated SGM strains were Mycobacterium avium complex (MAC) in 25/85 (29.41%) patients, M. xenopi in 20/85 (23.53%) patients, M. kansasii in 15/85 (17.65%) patients and M. peregrinum and M. gordonae in 5/85 (5.88%) patients each. Isolated rapid-growing mycobacteria (RGM) strains were M. abscessus in 8/85 (9.41%) patients, M. fortuitum in 4/85 (4.71%) patients and M. chelonae in 3/85 (3.53%) patients. Almost all patients (98%; 83/85) had comorbidities. Among 75 (88.24%) patients who completed follow-up, 59 (69.41%), 10 (11.76%) and 6 (7%), were cured, experienced relapse and died, respectively. CONCLUSION: In the present study, pulmonary NTM infections were more frequent compared to extrapulmonary disease forms. SGM were most common isolates with MACpulmonary disease the most frequently found. Comorbidities have an important role in NTM occurrence. Further investigation should focus on an NTM drug susceptibility testing.
Authors: J van Ingen; S A Bendien; W C M de Lange; W Hoefsloot; P N R Dekhuijzen; M J Boeree; D van Soolingen Journal: Thorax Date: 2009-02-12 Impact factor: 9.139
Authors: H Kotilainen; V Valtonen; P Tukiainen; T Poussa; J Eskola; A Järvinen Journal: Eur J Clin Microbiol Infect Dis Date: 2015-07-09 Impact factor: 3.267
Authors: Kelly M Pennington; Ann Vu; Douglas Challener; Christina G Rivera; F N U Shweta; John D Zeuli; Zelalem Temesgen Journal: J Clin Tuberc Other Mycobact Dis Date: 2021-05-08
Authors: Hye Ok Kim; Kyungjong Lee; Hee Kyoung Choi; Sangmi Ha; Sang Moo Lee; Gi Hyeon Seo Journal: Medicine (Baltimore) Date: 2019-11 Impact factor: 1.817